Fonseca C.,Vall dHebron Research Institute |
Server A.,Vall dHebron Universitary Hospital |
Esteves M.,Vall dHebron Research Institute |
Barastegui D.,Vall dHebron Research Institute |
And 3 more authors.
Lab Animal | Year: 2015
Regional anesthesia techniques, such as nerve blocks, are routinely used in humans and can contribute to multimodal approaches to pain management in research animals. Ultrasound guidance is an emerging aspect of regional anesthesia that has the potential to optimize local delivery and distribution of anesthetic agents, thereby reducing the amounts of these agents that must be administered. The authors developed an ultrasound-guided technique for effective block of the axillary brachial plexus in rabbits. They used this technique to carry out nerve block in 14 rabbits. The procedure was accomplished in a relatively short amount of time and achieved successful nerve block in all rabbits with no adverse effects. Sonographic visualization of the distribution of the local anesthetic ropivacaine led to administration of smaller anesthetic doses in eight of the rabbits without affecting the duration of nerve block. The authors conclude that their technique is feasible and safe and provides effective analgesia of the thoracic limb in rabbits. They recommend that this technique be integrated into multimodal approaches to pain management in rabbits undergoing thoracic limb surgery. Source
Vidal R.,Vall dHebron Universitary Hospital |
Barros-Tizon J.C.,Xeral Cies Universitary Hospital |
Galdiz J.B.,Hospital de Cruces |
Garcia-Talavera I.,Nuestra Senora Of Candelaria Universitary Hospital |
And 6 more authors.
Minerva Pneumologica | Year: 2010
Aim. In the perspective of postmarketing surveillance of human alpha-1 antitrypsin (AAT) products for intravenous administration, clinical studies following long-term augmentation therapy in significant cohorts of AAT-deficient subjects are needed. The main objective of this study was to assess tolerance of Trypsone®, a lyophilized and sterile preparation of AAT highly purified from human plasma, as chronic replacement therapy in AAT-deficient subjects with associated pulmonary emphysema. Furthermore, the safety of the study drug was evaluated as a secondary objective. Methods. This was a multicenter, prospective, non-controlled, observational clinical study with 23 individuals. Tolerance to the drug exposure was assessed by monitoring vital signs and considering adverse events (AEs) which took place during the AAT infusions. For safety evaluation, all AEs occurring to any participating subject were considered; from the first study drug exposure to the end of the prospective period of observation, regardless whether the event occurred during the infusions. Results. No clinically significant changes of vital signs were reported as AEs during the administration of the study drug. Only one, among 555 infusions, had an AE possibly related to the study drug. This AE consisted in a vasovagal reaction with arterial hypotension and dizziness which was classified as non-serious, of moderate intensity and expected. Regarding other AEs not occurring during the infusions, a total of 5 serious AEs were reported in 4 subjects but none of them were related to the study drug. Conclusion. Trypsone® represents a viable and safe treatment option for augmentation therapy with in AAT deficient individuals. Source
Alfonso P.,Research Center Biomedica En Red Of Enfermedades Raras Ciberer |
Alfonso P.,Miguel Servet Universitary Hospital |
Alfonso P.,Aragon Health science Institute ICS |
Pampin S.,University of Cantabria |
And 14 more authors.
Clinica Chimica Acta | Year: 2011
Background: Gaucher disease (GD) is a rare autosomal recessive disorder caused mainly by mutations in the glucocerebrosidase (GBA) gene. Great phenotypic variability has been observed among patients with the same genotype, suggesting other factors, such as polymorphic variants, might influence GD phenotypes. We previously reported the c.(-203)A>G (g.1256A>G) variant in exon 1 of the GBA gene in Spanish GD patients. Methods: We analyzed the frequency and transcriptional activity of the promoter carrying the G-allele using restriction isotyping, electrophoretic mobility shift assay, cell culture, transfection, and luciferase assays. Results: We found the variant is present at a similar frequency to the control group. In our patients, the G-allele was always found in combination with another mutation in the same allele, and patients carrying the c.(-203)A>G variant showed a more severe GD phenotype. The promoter containing the G-allele showed a 35% reduction in promoter activity when transfected into HepG2 cells. Conclusion: The c.(-203)A>G variant seems to be a polymorphism resulting in a decrease in activity of the GBA promoter. The change, per se, is not enough to elicit a GD phenotype, but it may produce a more severe phenotype in GD patients when combined with an already defective GBA protein. © 2010 Elsevier B.V. Source